SavedAdd your journal

Journals / E Journal of Cardiovascular Medicine / 2021 / Cilt: 9 - Sayı: 4

Resistant Hypertension and Atrial Fibrillation: How Important Is the Rhythm?

Ebru İpek Türkoğlu
Emine Çiğdem Kırçiçeği Çiçekdağ
Eser Şekercioğlu
Pages
184–191
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: When comparing RHT patients according to HR, AF patients were older (mean age: 73.5±7.6 vs. 61.7±11.2 years, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Resistant hypertension (RHT) identifies a high-risk population; however, the effect of concomitant atrial fibrillation (AF) in this patient group is understudied.
📊
Key Findings & Data:Consecutive 101 RHT patients were included in the study and divided into two groups according to HR, sinus rhythm (SR) or AF.
💡
Conclusion & Impact:Results: When comparing RHT patients according to HR, AF patients were older (mean age: 73.5±7.6 vs. 61.7±11.2 years, p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Resistant hypertension (RHT) identifies a high-risk population; however, the effect of concomitant atrial fibrillation (AF) in this patient group is understudied. The present study aimed to investigate the effect of heart rhythm (HR) in this population. Materials and Methods: The study was designed as a retrospective, single-center, closed cohort archive screening study in a given time and outpatient data were reviewed. Patients with secondary hypertension, pseudo-RHT and heart failure were eliminated. Consecutive 101 RHT patients were included in the study and divided into two groups according to HR, sinus rhythm (SR) or AF. Baseline demographics were compared, and the correlation between N-terminal pro-brain natriuretic peptide (NT-proBNP), left atrial diameter (LAD) and age were investigated. Results: When comparing RHT patients according to HR, AF patients were older (mean age: 73.5±7.6 vs. 61.7±11.2 years, p

🔖

Cite This Article

Türkoğlu, E. İ., Çiçekdağ, E. Ç. K., Şekercioğlu, E. (2022). Resistant Hypertension and Atrial Fibrillation: How Important Is the Rhythm?. E Journal of Cardiovascular Medicine, Cilt: 9 - Sayı: 4, 184–191. https://ajindex.com/articles/498213

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Williams B, Mancia G, Spiering W, et al. The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021- 104
  2. Townsend RR, Epstein M. Resistant Hypertension. Insights on evaluation and management in the post-SPRINT (systolic blood pressure intervention trial) era. Hypertension 2016;68:1073-80
  3. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Resistant hypertension characterized by increased aldosterone levels and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64
  4. Sarafidis PA, Bakris GL. Resistant hypertension an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57
  5. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:130-9
  6. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep 2002;4:221-8
  7. Chen Y, Sato H, Watanabe N, et al. Factors influencing left atrial volume in treated hypertension. J Cardiol 2012;60:133-8
  8. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4
  9. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68
  10. Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation. Doubts and certainties from basic and clinical studies. Circ Res 2018;122:352-68
  11. Rahman F, Yin X, Larson MG, et al. Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study. Hypertension 2016;68:597-605
  12. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension 2017;70:854-64
  13. Seccia TM, Caroccia B Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. Hypertension 2017;69:545-50
  14. Januzzi Jr JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:958-54
  15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-200
  16. Mueller